A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule.
Phase of Trial: Phase IV
Latest Information Update: 16 Dec 2013
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors Crucell
- 15 Sep 2011 Actual end date Apr 2011 added as reported by ClinicalTrials.gov.
- 15 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2011 New trial record